NBNigel J. Bundred

Nigel J. Bundred

*This is an algorithmically generated author record based on publicly available information.

Nigel J. Bundred has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice?

    by Andrew Pieri, James Harvey, Nigel Bundred

    Pleomorphic lobular carcinoma in situ of the breast: Can the evidence guide practice?


  • Ductal Carcinoma In Situ

    by Nigel J. Bundred, Nicola L. P. Barnes

  • 02-P017 Notch signalling in DCIS and invasive breast cancer

    by Rebecca Rock, Spyros Stylianou, Gillian Farnie, Robert B. Clarke, Nigel J. Bundred, Keith Brennan

  • Open Access

    Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

    by Fiona M Foster, Thomas W Owens, Jolanta Tanianis-Hughes, Robert B Clarke, Keith Brennan, Nigel J Bundred, Charles H Streuli

    Introduction: Inhibitor of apoptosis (IAPs) proteins are a family of proteins that can block apoptosis in normal cells and have been suggested to cause resistance to apoptosis in cancer. Overexpression of oncogenic receptor tyrosine kinases is common in breast cancer; in particular 20% of all cases show elevated Her2. Despite clinical success with the use of targeted therapies, such as Trastuzumab, only up to 35% of Her2-positive patients initially respond. We reasoned that IAP-mediated apoptosis resistance might contribute to this insensitivity to receptor tyrosine kinase therapy, in particular ErbB antagonists. Here we examine the levels of IAPs in breast cancer and evaluate whether targeting IAPs can enhance apoptosis in response to growth factor receptor antagonists and TRAIL. Methods: IAP levels were examined in a breast cancer cell line panel and in patient samples. IAPs were inhibited using siRNA or cell permeable mimetics of endogenous inhibitors. Cells were then exposed to TRAIL, Trastuzumab, Lapatinib, or Gefitinib for 48 hours. Examining nuclear morphology and staining for cleaved caspase 3 was used to score apoptosis. Proliferation was examined by Ki67 staining. Results: Four members of the IAP family, Survivin, XIAP, cIAP1 and cIAP2, were all expressed to varying extents in breast cancer cell lines or tumours. MDAMB468, BT474 and BT20 cells all expressed XIAP to varying extents. Depleting the cells of XIAP overcame the intrinsic resistance of BT20 and MDAMB468 cells to TRAIL. Moreover, siRNA-based depletion of XIAP or use of a Smac mimetic to target multiple IAPs increased apoptosis in response to the ErbB antagonists, Trastuzumab, Lapatinib or Gefitinib in Her2-overexpressing BT474 cells, or Gefitinib in EGFR-overexpressing MDAMB468 cells. Conclusions: The novel findings of this study are that multiple IAPs are concomitantly expressed in breast cancers, and that, in combination with clinically relevant Her2 treatments, IAP antagonists promote apoptosis and reduce the cell turnover index of breast cancers. We also show that combination therapy of IAP antagonists with some pro-apoptotic agents (for example, TRAIL) enhances apoptosis of breast cancer cells. In some cases (for example, MDAMB468 cells), the enhanced apoptosis is profound.


  • Open Access

    Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity

    by G R Wilson, A Cramer, A Welman, F Knox, R Swindell, H Kawakatsu, R B Clarke, C Dive, N J Bundred

    Overexpression and/or activity of c-Src non-receptor tyrosine kinase is associated with progression of several human epithelial cancers including breast cancer. c-Src activity in ‘pure’ ductal carcinoma in situ (DCIS) was measured to assess whether this predicts recurrence and/or correlates with HER2 expression and other clinical parameters. Activated c-Src levels were evaluated in DCIS biopsies from 129 women, with median follow-up at 60 months. High levels of activated c-Src correlated with HER2 positivity, high tumour grade, comedo necrosis and elevated epithelial proliferation. In univariate analysis, high activated c-Src level associated with lower recurrence-free survival at 5 years (P=0.011). Thus, high c-Src activity may identify a subset of DCIS with high risk of recurrence or progression to invasive cancer where therapeutics targeting c-Src may benefit this patient subset.


  • Open Access

    Letrozole: A Well-Tolerated and Effective Treatment for Breast Cancer

    by Nigel J Bundred

    Letrozole, an aromatase inhibitor, demonstrates consistent superiority over tamoxifen in various treatment settings, has the only significant survival advantage according to results from a Phase III randomized trial, and is the only aromatase inhibitor approved as an extended adjuvant therapy in the treatment of breast cancer. Initial adjuvant letrozole significantly prolongs disease-free survival, especially reducing the risk of distant metastasis, and offers a significant disease-free survival benefit to patients at an increased risk of relapse (node-positive and chemotherapy-treated patients) when compared with tamoxifen. These findings led to its recommendation as an initial adjuvant therapy in the latest St Gallen guidelines. Similar findings were reported when letrozole was administered after completion of 5 years of adjuvant tamoxifen. The benefit of letrozole also increases with the duration of treatment. Overcoming the development of resistance to endocrine therapy is under investigation. As a potent aromatase inhibitor, letrozole is the ideal drug for tailored combination treatment regimens of the future.


  • Open Access

    Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo

    by Fredrik Wärnberg, Daniel White, Elizabeth Anderson, Fiona Knox, Robert B Clarke, Julie Morris, Nigel J Bundred

    Introduction: The ras pathway is essential for cell growth and proliferation. The effects of R115777, a farnesyl transferase inhibitor, were investigated in cancer cell lines expressing varying levels of growth factor receptors and with differing ras status. Effects on tumour xenografts and human ductal carcinoma in situ (DCIS) of the breast in a xenograft mouse model were also tested. Method: In vitro, the concentrations required to reduce cell numbers by 50% (50% inhibitory concentration) were established (MDA-MB231, MCF-7, MCF-7/HER2-18, BT-474, SK-BR3 and SKOV3). Human DCIS was implanted in nude mice or, in separate experiments, cultured cells were injected (MDA-MB231, MCF-7/HER2-18, SKOV3) and allowed to form tumours. Proliferation and apoptosis were determined by immunohistochemistry in xenografts and cell tumours. Results: The 50% inhibitory concentrations varied a hundred-fold, from 39 nmol/l (± 26 nmol/l) for SKBR3 to 5.9 μmol/l(± 0.8 μmol/l) for MDA-MB231. In MCF-7/HER2-18 and SKOV3 cells the levels of tumour growth inhibition were approximately 85% and 40%, respectively. There was a significant decrease in the cell turnover index (CTI; proliferation/apoptosis). In MDA-MB 231 with activated k-ras no inhibition was observed. In treated DCIS xenografts proliferation decreased and apoptosis increased. The CTI ratio between the start and 1 and 2 weeks of treatment were 1.99 and 1.50, respectively, for controls and 0.85 (P = 0.005) and 0.75 (P = 0.08) for treated xenografts. Conclusion: Treatment with the farnesyl transferase inhibitor reduced cell growth in vitro and cell tumour growth in vivo. In DCIS treatment resulted in a reduced CTI. R115777 is a promising treatment for breast cancer but the relation between effect and growth factor receptor and ras status has to be established.


  • Panorama. The Hospital That Failed Women

    by Nigel Bundred

    T his episode of the BBC's flagship documentary Panorama —the latest of several recent episodes to have focused on NHS related issues—looked at whether some women treated for breast cancer at Bradford NHS Trust had missed out on a critical part of their treatment. The basis for the programme was a statistical analysis of data from the Northern and Yorkshire Cancer Registry, which includes Bradford, carried out by Michel Coleman, professor of epidemiology at the London School of Hygiene and Tropical Medicine, and deputy chief medical statistician at the Office for National Statistics from 1995 to 2004. Panorama 's claims related to radiotherapy, widely recognised to be an integral part of treatment after breast conserving surgery. Since 1995 Department of Health guidelines have been that all women who undergo breast conserving surgery should also receive radiotherapy. Professor Coleman, who analysed data on almost 30 000 women with breast cancer who had been treated in Yorkshire hospitals between 1982 and 2003, said that there was “a strikingly different pattern of breast conserving surgery and radiotherapy” for women treated by one consultant in Bradford “than all other experienced surgeons.” Radiotherapy was given after breast conserving surgery in Bradford through the 1990s only in between …

  • Open Access

    Potential use of COX-2–aromatase inhibitor combinations in breast cancer

    by N J Bundred, N L P Barnes

    Cyclooxygenase-2 (COX-2) is overexpressed in several epithelial tumours, including breast cancer. Cyclooxygenase-2-positive tumours tend to be larger, higher grade, node-positive and HER-2/neu-positive. High COX-2 expression is associated with poor prognosis. Cyclooxygenase-2 inhibition reduces the incidence of tumours in animal models, inhibits the development of invasive cancer in colorectal cancer and reduces the frequency of polyps in familial adenomatous polyposis (FAP). These effects may be as a result of increased apoptosis, reduced angiogenesis and/or proliferation. Studies of COX-2 inhibitors in breast cancer are underway both alone and in combination with other agents. There is evidence to suggest that combining COX-2 inhibitors with aromatase inhibitors, growth factor receptor blockers, or chemo- or radiotherapy may be particularly effective. Preliminary results from combination therapy with celecoxib and exemestane in postmenopausal women with advanced breast cancer showed that the combination increased the time to recurrence. Up to 80% of ductal carcinomas in situ (DCISs) express COX-2, therefore COX-2 inhibition may be of particular use in this situation. Cyclooxygenase-2 expression correlates strongly with expression of HER-2/neu. As aromatase inhibitors appear particularly effective in patients with HER-2/neu-positive tumours, the combination of aromatase inhibitors and COX-2 inhibitors may be particularly useful in both DCIS and invasive cancer.


  • Open Access

    The effects of aromatase inhibitors on lipids and thrombosis

    by N J Bundred

    Oestrogen is known to influence blood lipid levels and though its cardioprotective effects are less clear than once thought, there remains concern that reduction of oestrogen levels during hormonal treatment for breast cancer may have an adverse effect on cardiovascular risk. While tamoxifen has been shown to improve lipid profiles, the aromatase inhibitors have a very different mode of action and do not possess the oestrogen-agonistic effects of tamoxifen. At present, there are few data on the effects of these agents on lipid profiles. Available data are mixed, but suggest that the different aromatase inhibitors have different effects on lipid profiles. Some studies show anastrozole as generally having little effect on lipids, while others have indicated adverse effects on lipid profiles/increased hypercholesterolaemia. Letrozole has been associated with adverse effects on lipid profiles in some studies, including BIG 1-98, but short-term data from randomised trials do not show increased cardiovascular morbidity. By contrast, exemestane, which has been studied in slightly more detail, may either have little effect or may be associated with slightly improved lipid profiles. In general, the changes have been small and are likely to be of little relevance in women with advanced breast cancer, but if these agents come to be used in early breast cancer, their impact on lipid profiles may become more important. Many studies are currently underway with the aromatase inhibitors, with safety assessments including monitoring lipid levels. The results of these studies are keenly awaited.